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SUMMARY 
Background. Necitumumab is a second-generation recombinant human immunoglobulin G1 
EGFR monoclonal antibody that competitively inhibits ligand binding. We aimed to compare 
necitumumab plus pemetrexed and cisplatin with pemetrexed and cisplatin alone in patients 
with previously untreated, stage IV, non-squamous non-small-cell lung cancer (NSCLC). 
Methods. We did this randomised, open-label, controlled phase 3 study at 103 sites in 20 
countries. Patients aged 18 years or older, with an Eastern Cooperative Oncology Group 
(ECOG) performance status of 0-2 and adequate organ function, were randomly assigned 1:1 
to treatment with a block randomisation scheme (block size of four) via a telephone-based 
interactive voice-response system or interactive web-response system. Patients received either 
cisplatin 75 mg/m
2
 and pemetrexed 500 mg/m
2
 on day 1 of a 3-week cycle for a maximum of 
six cycles alone, or with necitumumab 800 mg on days 1 and 8. Necitumumab was continued 
after the end of chemotherapy until disease progression or unacceptable toxic effects. 
Randomisation was stratified by smoking history, ECOG performance status, disease 
histology, and geographical region. Patients and study investigators were not masked to group 
assignment. The primary endpoint was overall survival. Efficacy analyses were by intention 
to treat. This trial is registered with ClinicalTrials.gov, number NCT00982111. 
Findings. Between Nov 11, 2009, and Feb 2, 2011, we randomly assigned 633 patients to 
receive either necitumumab plus pemetrexed and cisplatin (n=315) or pemetrexed and 
cisplatin alone (n=318). Enrolment was stopped on Feb 2, 2011, after a recommendation from 
the independent data monitoring committee. There was no significant difference in overall 
survival between treatment groups, with a median overall survival of 11·3 months (95% CI 
9·5-13·4) in the necitumumab plus pemetrexed and cisplatin group versus 11·5 months (10·1-
13·1) in the pemetrexed and cisplatin group (hazard ratio 1∙01 [95% CI 0∙84-1∙21]; p=0∙96). 
The incidence of grade 3 or worse adverse events, including deaths, was higher in the 
necitumumab plus pemetrexed and cisplatin group than in the pemetrexed and cisplatin group; 
in particular, deaths regarded as related to study drug were reported in 15 (5%) of 304 patients 
in the necitumumab group versus nine (3%) of 312 patients in the pemetrexed and cisplatin 
group. Serious adverse events were likewise more frequent in the necitumumab plus 
pemetrexed and cisplatin group than in the pemetrexed and cisplatin group (155 [51%] of 304 
vs 127 [41%] of 312 patients). Patients in the necitumumab plus pemetrexed and cisplatin 
group had more grade 3-4 rash (45 [15%] of 304 vs one [<1%] of 312 patients in the 
pemetrexed and cisplatin alone group), hypomagnesaemia (23 [8%] vs seven [2%] patients), 
and grade 3 or higher venous thromboembolic events (23 [8%] vs 11 [4%] patients) than did 
those in the pemetrexed and cisplatin alone group. 
Interpretation. Our findings show no evidence to suggest that the addition of necitumumab 
to pemetrexed and cisplatin increases survival of previously untreated patients with stage IV 
non-squamous NSCLC. Unless future studies identify potentially useful predictive 
biomarkers, necitumumab is unlikely to provide benefit in this patient population when 
combined with pemetrexed and cisplatin. 
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INTRODUCTION 
Non-small-cell lung cancer (NSCLC) is a heterogeneous disease with respect to tumour 
histology and molecular profile.
1-2
 Patients with EGFR wild-type, ALK translocation-negative 
non-squamous NSCLC (adenocarcinoma, large-cell carcinoma, and other non-squamous 
histology), and a good performance status, might be offered a wide choice of first-line 
regimens consisting of a platinum-based doublet of cisplatin or carboplatin combined with 
pemetrexed, a taxane, gemcitabine, or vinorelbine, with or without bevacizumab.
3
 The 
presence in tumours of sensitising mutations of EGFR or ALK translocations—driver lesions 
predictive of outcome for particular targeted drugs—offers the possibility of specific, 
pathway-directed systemic therapy for some patients with adenocarcinoma.
4-6
 However, 
tumour EGFR mutation status does not seem to be associated with efficacy of EGFR antibody 
therapy.
7
 In the past few years, expansion of first-line treatment options for patients with non-
squamous NSCLC has been reflected in improvements in overall survival. 
Most advanced NSCLCs express EGFR, and aberrant function of the EGFR pathway seems to 
be a key factor in the development of some NSCLCs.
8
 The randomised phase 3 FLEX study 
showed that addition of the EGFR antibody cetuximab to cisplatin plus vinorelbine 
significantly improved overall survival (hazard ratio [HR] 0∙871 [95% CI 0∙762-0∙996]; 
p=0∙044), but not progression-free survival (0∙943 [0∙825-1∙077]; p=0∙39) in the first-line 
treatment of patients with EGFR-expressing advanced NSCLC.
8
 This improvement in overall 
survival was accompanied by significant adverse effects in the cetuximab group, in particular 
an increased incidence of febrile neutropenia, an adverse event that was prevalent in the 
chemotherapy group. Nevertheless, the FLEX study provided a rationale for the testing of 
other EGFR antibodies in this setting. 
Necitumumab is a second-generation recombinant human immunoglobulin G1 (IgG1) EGFR 
monoclonal antibody that binds EGFR with high affinity, competing with the natural ligands 
and thereby preventing receptor activation by all known ligands and thus inhibiting 
downstream signalling.
9
 For first-line treatment of patients with advanced non-squamous 
NSCLC, pemetrexed and cisplatin is an established chemotherapy regimen.
10,11
 In murine 
NSCLC xenograft models, addition of necitumumab to pemetrexed and cisplatin resulted in a 
substantial increase in anti-tumour activity (unpublished data), suggesting that this regimen 
was appropriate for use in our present study. 
We did the INSPIRE study to investigate whether addition of necitumumab to pemetrexed 
and cisplatin would improve survival in the first-line treatment of patients with advanced non-
squamous NSCLC. We postulated that the choice of pemetrexed and cisplatin as the 
chemotherapy regimen when combined with an EGFR antibody would result in a lower 
incidence of febrile neutropenia than did the cisplatin and vinorelbine regimen used in the 
FLEX study. We also expected to minimise the rate of hypersensitivity reactions on the basis 
of the human constitution of necitumumab. In parallel, the phase 3 SQUIRE study
12
 assessed 
the efficacy and safety of necitumumab plus gemcitabine and cisplatin as first-line treatment 
for patients with advanced squamous NSCLC. 
 
METHODS 
Study design and patients 
We did this open-label, randomised, controlled phase 3 study at 103 sites in 20 countries   
(appendix).   Full inclusion and exclusion criteria are in the appendix. Briefly, eligible patients 
were aged 18 years or older with histologically or cytologically confirmed stage IV 
(according to the American Joint Committee on Cancer staging system
13
) non-squamous 
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NSCLC who had not received chemotherapy for the treatment of advanced disease. Other key 
inclusion criteria included measurable disease as defined by RECIST 1.0 criteria,
14 
an Eastern 
Cooperative Oncology Group (ECOG) performance status of 0-2, and adequate organ 
function (white blood cell count of ≥3000 cells per µL, with an absolute neutrophil cell count 
of ≥1500 cells per µL, a platelet count of ≥100000 cells per µL, and a haemoglobin 
concentration of ≥9∙5 g/dL; total bilirubin of ≤1∙5xfhe upper limit of normal [ULN] and 
aspartate aminotransferase and alanine aminotransferase of ≤5∙0x the ULN in the presence of 
liver metastases, or of ≤2∙5x the ULN in the absence of liver metastases; and serum creatinine 
of ≤1∙2xthe ULN or a calculated creatinine clearance of >50 mL/min). The availability of 
archived tumour tissue for biomarker analysis was also an inclusion criterion. 
Key exclusion criteria included symptomatic brain metastases, clinically significant third-
space fluid retention requiring repeated drainage, peripheral neuropathy of grade 2 or worse 
and major surgery or investigational therapy in the 4 weeks before randomisation. Patients 
were also excluded if they had superior vena cava syndrome contraindicating hydration; 
clinically relevant coronary artery disease or uncontrolled congestive heart failure (New York 
Heart Association class III or IV
15
); myocardial infarction within 6 months before 
randomisation; an ongoing or active infection (needing antibiotics), including active 
tuberculosis or known infection with HIV; a history of clinically significant neurological or 
psychiatric disorders, including dementia, seizures, or bipolar disorder, potentially precluding 
protocol compliance; any other serious uncontrolled medical disorders or psychological 
disorder that would, in the opinion of the investigator, restrict the patient's ability to complete 
the study or sign an informed consent document; a known allergy or history of 
hypersensitivity reaction to any of the treatment components, including any ingredient used in 
the formulation of necitumumab, or any other contraindication to one of the given treatments; 
a concurrent active malignancy other than adequately treated basal-cell carcinoma of the skin 
or preinvasive carcinoma of the cervix (a patient with previous history of malignancy other 
than NSCLC was eligible, provided that they had been free of disease for ≥3 years); a known 
history of drug abuse; or if the patient was pregnant or breastfeeding. 
All patients provided written informed consent. This study was done in accordance with the 
International Conference on Harmonization and good clinical practice guidelines and was 
approved by the local ethics committees at each study centre. 
 
Randomisation and masking 
Patients were randomly assigned (1:1), with a block randomisation scheme (block size of 
four) via a telephone-based interactive voice-response system or interactive web-response 
system, to receive necitumumab plus pemetrexed and cisplatin or pemetrexed and cisplatin 
alone. Randomisation was stratified by smoking history (non-smoker vs ex-light smoker vs 
smoker), ECOG performance status (0-1 vs 2), disease histology (adenocarcinoma or large-
cell carcinoma vs other), and geographical region (North America, Europe, Australia vs South 
America, South Africa, Asia [India]). Patients received the first dose of study drug within 7 
days of randomisation. 
After the first treatment session, we expected that the likely occurrence of acneiform rash in 
patients in the necitumumab plus pemetrexed and cisplatin group would unmask most patients 
and investigators to treatment assignment. For this reason, we did the study open-label. 
However, the aggregate clinical data provided to the sponsor during the study were masked to 
treatment assignment to preserve the integrity of the trial. The sponsor of the study had 
unmasked access only to serious adverse event data. 
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Procedures 
Chemotherapy comprised intravenous cisplatin 75 mg/m
2 
and pemetrexed 500 mg/m
2
 on day 
1 of a 3-week cycle, for a maximum of six cycles. Necitumumab at an absolute dose of 800 
mg was given intravenously on days 1 and 8. Before administration of pemetrexed, patients 
received oral corticosteroid, folic acid (350-1000 µg orally, once daily), and vitamin B12 
supplementation, according to the pemetrexed label. We allowed dose modifications of all 
study drugs according to protocol-defined criteria (appendix). In particular, necitumumab 
dose modification was allowed after occurrence of a reversible grade 3 or 4 necitumumab-
related adverse event (ie, an event that resolved to grade 2 or lower—eg, fatigue, anorexia, 
fever) that needed a delay of treatment for up to 6 weeks after day 1 of the most recent 
treatment cycle. In this setting, necitumumab could be re-administered at a reduced dose of 
600 mg if necessary. We allowed a second dose reduction to 400 mg for this level of event 
(grade 3 or 4). Events that needed more than two dose reductions warranted automatic 
discontinuation of necitumumab. Patients were withdrawn from treatment if they developed a 
grade 3 or 4 infusion reaction. 
After six cycles of study therapy, patients without progressive disease in the necitumumab 
group continued with necitumumab on the same treatment schedule until radiographically 
documented progressive disease or the occurrence of unacceptable toxic effects. Patients in 
the chemotherapy alone group were observed until radiographically documented progressive 
disease. Study therapy was discontinued on occurrence of progressive disease or unacceptable 
toxic effects. 
We assessed tumour response, according to RECIST 1.0, by CT or MRI at baseline (within 21 
days before randomisation) and then every 6 weeks after the first dose of study therapy until 
radiographically documented progressive disease. Complete blood counts and serum 
chemistry were obtained at baseline and on days 1 and 8 of each cycle until discontinuation of 
chemotherapy, and before treatment on day 1 of each cycle thereafter for patients in the 
necitumumab group. Coagulation profile and urinalysis assessments were done at baseline, on 
day 1 of cycle 1, and every 6 weeks thereafter. For female patients, a pregnancy test was done 
at baseline and every 6 weeks thereafter. 
Treatment-emergent adverse events were reported according to the Medical Dictionary for 
Regulatory Activities (version 12.0)
16
 and were graded with the National Cancer Institute-
Common Terminology Criteria for Adverse Events (version 3.0).
17
 An independent data 
monitoring committee monitored safety on a regular basis. We assessed patient health status 




 At each scheduled 
timepoint, assessment of the Lung Cancer Symptom Scale was done before EuroQol-5D. We 
assessed expression of tumour EGFR protein by immuno-histochemistry with the EGFR 
PharmDx Kit (Dako, Carpinteria, CA). We classified the level of expression by 
immunohistochemistry score on a continuous scale of 0-300 (H-score), as previously 
described.
20,21




The primary endpoint was overall survival, defined as the time from randomisation to death 
from any cause. Secondary endpoints were: progression-free survival, defined as time from 
randomisation to radiographic progression or death from any cause; objective response, 
defined as the proportion of patients who had a best response of complete response or partial 
response; time to treatment failure, defined as time from the date of randomisation until the 
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date of the first radiographical documentation of progressive disease, death by any cause, 
discontinuation of treatment for any reason, or initiation of new anticancer therapy; safety; 
self-reported health status (EuroQol-5D index score, Visual Analog Scale score, and Lung 




Using a two-sided log-rank test at the 5% significance level, the original planned sample size 
of 947 patients would have given a power of 85% for detection of a significant improvement 
in overall survival, from 11∙0 months for pemetrexed and cisplatin11 to 13∙75 months for 
necitumumab plus pemetrexed and cisplatin, as denoted by an HR for necitumumab plus 
pemetrexed and cisplatin versus pemetrexed and cisplatin of 0∙80. After inclusion of 633 
patients, enrolment was stopped after a recommendation from the independent data 
monitoring committee. The amended final analysis was planned when at least 474 deaths 
were recorded and gave a power of 68% according to the assumptions that governed the 
original power calculation. 
We assessed efficacy in the intention-to-treat population, which included all randomised 
patients. Safety was assessed in patients who received any dose of study drug and was 
analysed according to actual therapy received. We estimated overall and progression-free 
survival with the Kaplan-Meier method and compared both between treatment groups with 
the log-rank test, stratified by the randomisation strata. We estimated HRs and 95% CIs from 
stratified Cox proportional hazards models. We compared the proportion of patients achieving 
an objective response in each treatment group with the Cochran-Mantel-Haenszel test, with 
adjustment for the stratification variables. The overall significance level was set at 0∙05; no 
adjustment was done for multiple testing for the secondary endpoints. 
Findings from an immunohistochemistry analysis of the FLEX study suggested that a tumour 
EGFR H-score of 200 or more was predictive for cetuximab benefit; this finding was apparent 
both in the overall trial population and in adenocarcinoma and squamous-cell-carcinoma 
subgroups.
20
 In an exploratory analysis of our study, we investigated whether an EGFR H-
score of 200 or more was predictive for necitumumab benefit by comparing treatment 
outcome in high (H-score ≥200) versus low (H-score <200) EGFR expression groups with 
Cox regression analysis. This analysis was done in the translational research population, 
comprising patients in the safety population who had a valid (ie, calculable for that patient 
from available data) non-missing result for EGFR H-score, and who were enrolled for more 
than two cycles before the decision was made to terminate enrolment. 
We analysed data with SAS (version 9.1.3). This study is registered with ClinicalTrials.gov, 
number NCT00982111. 
 
Role of the funding source 
The funder of the study was responsible for data management, commissioning of laboratory 
investigations, and statistical analyses, and designed the study in conjunction with LP-A, NT, 
FRH, and MAS (steering committee investigators). The funder interpreted data in 
collaboration with the authors and commissioned drafting of the manuscript. The steering 
committee had full access to all the data in the study and had the final responsibility for the 
decision to submit for publication. 
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RESULTS 
Study enrolment began on Nov 11, 2009. After a series of meetings between June 14, 2010, 
and Jan 31, 2011, the independent data monitoring committee recommended that study 
enrolment be stopped, and necitumumab treatment discontinued in patients who had not 
completed two cycles of treatment. This recommendation was made based on data of non-
fatal and fatal thromboembolic events from the sponsor's serious adverse event database and 
on the overall number of deaths from all causes shown in the clinical database, which were 
unbalanced against the experimental group. These findings led the independent data 
monitoring committee to conclude that the investigational treatment was disadvantageous to 
patients. A statistical time-to-event analysis done on Jan 31, 2011, showed that most fatal 
thromboembolic events had happened within the first two cycles of therapy, and, based on 
these results, patients who had completed two cycles of treatment (defined as completion of 
cycle 2, day 8) were allowed to continue study treatment with necitumumab. Patients who 
continued receiving necitumumab were asked to provide informed consent to continue. 
After the recommendation of the data monitoring committee, the sponsor, in conjunction with 
the steering committee, halted enrolment on Feb 2, 2011. Figure 1 shows the resulting study 
profile. We randomly assigned 633 patients to receive necitumumab plus pemetrexed and 
cisplatin (n=315) or pemetrexed and cisplatin alone (n=318); these patients constituted the 
intention-to-treat population. Baseline characteristics were balanced between the treatment 
groups (table 1). The safety population comprised 616 patients who received any dose of 
study drug. 
Exposure to chemotherapy was similar between treatment groups (appendix). The median 
relative dose intensity of necitumumab was 93% (IQR79∙7-100∙0). Of the 301 patients who 
received necitumumab plus pemetrexed and cisplatin, and whose serum was analysed for the 
presence of anti-necitumumab antibodies, 37 (12%) patients had positive samples at any time 
during the study and 13 (6%) of 229 patients had positive samples after treatment; nine    
(3%) patients had treatment-emergent positive samples. Of the 13 patients with positive 
samples after treatment, all had transient positive samples (defined as either one positive 
sample or two or more non-consecutive positive samples) and none had persistent positive 
samples (defined as at least two consecutive, positive samples). The overall frequency of 
treatment-emergent antibody positive samples was considered too low to allow any further 
analysis. 
The data cutoff was Nov 14, 2012, at which time 482 (76%) patients had died (censoring rate 
24%). The median duration of follow-up was 24∙5 months (IQR 22∙3-27∙5) for the 
necitumumab plus pemetrexed and cisplatin group and 25∙6 months (IQR 22∙5-27∙4) for the 
pemetrexed and cisplatin group. There was no significant difference in overall survival 
between treatment groups (table 2, figure 2). No clear differences in overall survival were 
noted across subgroups (appendix). There was no significant difference between treatment 
groups for progression-free survival (figure 2), objective response, or disease control (table 2). 
Time to treatment failure was shorter in patients in the necitumumab plus pemetrexed and 
cisplatin group than in those in the pemetrexed and cisplatin group (table 2); however, this 
finding might be confounded by the decision to stop treatment early in some patients in the 
necitumumab group. Systemic post-study anticancer therapy was moderately balanced 
between the treatment groups; the most frequently used drugs in both groups were docetaxel 
and erlotinib (appendix). 
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Figure 1. Trial profile 
 
*Two patients were counted twice in error in the total number of screened patients. †Two patients were 
randomly assigned to the necitumumab plus pemetrexed and cisplatin group, but incorrectly received treatment 
with pemetrexed and cisplatin alone. These patients were therefore considered as part of the necitumumab plus 
pemetrexed and cisplatin group of the intention-to-treat population, but of the pemetrexed and cisplatin group for 
analyses of safety. ‡Patients who completed all planned cycles of chemotherapy. §Radiographically documented. 
 
We investigated the effect of level of EGFR protein expression on outcome in the 
translational research population, comprising 490 patients who were assessable for EGFR H-
score and who were enrolled for more than two cycles before enrolment was stopped 
(appendix). This later restriction avoided possible confounding of the analysis after the 
recommendation to stop enrolment and the early withdrawal of therapy for some patients in 
the experimental group. However, there were no relevant differences in baseline 
characteristics and outcomes between the subset of patients included in the translational 
research population and those of the safety population, or between the treatment groups of this 
subpopulation (data not shown). H-score was high (≥200) in 200 (41%) of 490 assessable 
patients, and low (<200) in 290 (59%) patients (appendix). In both the high and low EGFR 
protein-expression groups, there were no significant differences between treatment groups for 
overall survival (figure 2), progression-free survival (figure 2), or response, and no significant 
interaction between treatment and EGFR-expression groups (appendix). In the investigation 
of the predictive value of H-score as a continuous covariate, there were no statistically 
significant differences between groups (estimated at different levels of H-score) in terms of 
overall or progression-free survival or objective response, and no significant interaction 
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between treatment and H-score as a continuous variable (appendix). However, we noted that 
patients with high tumour EGFR expression had a significantly lower risk of death versus 
those with low EGFR expression in both the necitumumab group and the control group 
(appendix). Correspondingly, we recorded better outcomes in both treatment groups for high 
EGFR expression compared with low expression for progression-free survival and response 
(appendix). 
 
Table 1 . Baseline characteristics 







Sex   
            Male 214 (68%) 210 (66%) 
            Female 101 (32%) 108 (34%) 
1 Age (years) 61(55-67) 60 (53-67) 
Age group (years)   
 <65 200 (63%) 216 (68%) 
 ≥65 115 (37%) 102 (32%) 
 <70 263 (83%) 267 (84%) 
 ≥70 52(17%) 51 (16%) 
Ethnic origin   
 White 292 (93%) 298 (94%) 
 Asian 2 (<1%) 0 
 Other 21 (7%) 20 (6%) 
ECOG performance status   
 0 115 (37%) 132 (42%) 
 1 183 (58%) 166 (52%) 
 2 16(5%) 20 (6%) 
 Missing 1 (<1%) 0 
Smoking history   
 Non-smoker 51 (16%) 53 (17%) 
 Ex-light smoker 26 (8%) 27(8%) 
 Smoker 238 (76%) 238 (75%) 
Disease histology   
 Adenocarcinoma 281 (89%) 286 (90%) 
 Large-cell carcinoma 26 (8%) 25 (8%) 
 Other 7(2%) 7(2%) 
 Missing 1 (<1%) 0 
Previous anticancer therapy   
 Surgery 83 (26%) 91 (29%) 
 Radiotherapy 33 (10%) 41 (13%) 
 Systemic (adjuvant or 9 (3%) 11 (3%) 
 neoadjuvant)   
Data are n (%) or median (IQR). ECOG=Eastern Cooperative Oncology Group. 
 
220 (72%) of 304 patients in the necitumumab plus pemetrexed and cisplatin group and 185 
(59%) of 312 patients in the pemetrexed and cisplatin group had one or more grade 3 or 
higher treatment-emergent adverse events (appendix). The most common events according to 
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system organ class were blood and lymphatic system disorders and gastrointestinal disorders 
(appendix). Grade 3 or worse adverse events, according to preferred terms, that were more 
common in the necitumumab plus pemetrexed and cisplatin group than the pemetrexed and 
cisplatin group included rash, hypomagnesaemia, and asthenia (appendix). 
We recorded adverse events leading to delay or modification of at least one study drug in 144 
(47%) of 304 patients in the necitumumab plus pemetrexed and cisplatin group and 98 (31%) 
of 312 patients in the pemetrexed and cisplatin group. The most frequent of these events in the 
necitumumab plus pemetrexed and cisplatin group were skin and subcutaneous disorders and 
gastrointestinal disorders. Adverse events leading to discontinuation of at least one study drug 
were reported for 77 (25%) of 304 patients in the necitumumab plus pemetrexed and cisplatin 
group (most commonly, skin, and subcutaneous tissue disorders) and 51 (16%) of 312 patients 
in the pemetrexed and cisplatin group (most commonly, investigations [a system organ class 
that includes laboratory tests and vital signs]). 
Including those events related to progressive disease, 49 (16%) of 304 patients in the 
necitumumab plus pemetrexed and cisplatin group and 32 (10%) of 312 patients in the 
pemetrexed and cisplatin group died from an adverse event (appendix). These events were 
regarded as related to study treatment in 15 (5%) of 304 patients in the necitumumab plus 
pemetrexed and cisplatin group and nine (3%) of 312 patients in the control group. Serious 
adverse events were reported more frequently in the necitumumab plus pemetrexed and 
cisplatin group than in the pemetrexed and cisplatin group (155 [51%] of 304 vs 127 [41%] of 
312 patients). 
To further explore safety, we defined composite categories on the basis of the known safety 
profiles of other EGFR antibodies or clinical experience with necitumumab (table 3). The 
incidence of grade 3 or worse venous thromboembolic events was higher in the necitumumab 
plus pemetrexed and cisplatin group than in the pemetrexed and cisplatin group (table 3). 
Review of all available data did not identify any baseline risk factor that might have been 
predictive of such events for patients in the necitumumab plus pemetrexed and cisplatin 
group. Other adverse events of interest that were more frequent in the necitumumab plus 
pemetrexed and cisplatin group than in the pemetrexed and cisplatin group included skin 
reactions—a class effect of EGFR-targeting drugs (table 3). 
Health status was similar in both treatment groups (data not shown). In particular, the 
responses to the nine individual items of the Lung Cancer Symptom Scale, the average 
symptom burden index, the quality-of-life item, and total score were generally similar 
between treatment groups at baseline and from cycles 1 to 6 (data not shown). Similarly, the 
EuroQol-5D index and visual analogue scores by assessment visit were also generally 
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Table2: Efficacy endpoints 






Overall survival   
Deaths 236(75%) 246 (77%) 
Median (95% CI; months) 11∙3 (9-5-13-4) 11∙5 (10-1-13-1) 
Hazard ratio (95% CI)* 1∙01 (0-84-1-21)  
Log-rank p value*  
Rate (95% CI) 
0-96  
 6 month 70% (65-75) 74% (69-79) 
 1 year 47% (42-53) 49% (43-54) 
Progression-free survival   
Deaths or disease progression 231 (73%) 239 (75%) 
Median (95% CI; months) 5-6(5-1-6-0) 5-6(4-8-5-7) 
Hazard ratio (95% CI)* 0-96(0-80-1-16)  
Log-rank p value*  
Rate (95% CI) 
0-66  
 6 month 44% (38-50) 40% (34-45) 
Time to treatment failure †   
Events 305(97%) 305 (96%) 
Median (95% CI; months) 3-5(3-2-3-9) 4-3(3-3-4-8) 
Hazard ratio (95% CI)* 1-18 (1-00-1-39)  
Log-rank p value*  
Rate (95% CI) 
0-046 .. 
 3 month 59% (53-64) 58% (53-63) 
 6 month 22% (18-27) 31% (26-37) 
Response   
Best overall   
 Complete response 0 4(1%) 
 Partial response 98 (31%) 98 (31%) 
 Stable disease 133 (42%) 133 (42%) 
 Progressive disease 32 (10%) 44 (14%) 
 Not assessable 11 (4%) 12 (4%) 
 Missing 41 (13%) 27(9%) 
Proportion of patients achieving an objective 
response (%; 95% CI) 
98 (31%; 26-36) 102 (32%; 27-37) 
 Odds ratio (95% CI)* 0-96(0-68-1-34) .. 
 Cochran-Mantel-Haenszel p value* 0-79 .. 
Proportion of patients achieving disease 
control† (%; 95% CI) 
231 (73%; 68-78) 235 (74%; 69-78) 
Data are n (%), unless otherwise indicated. *Stratified by randomisation strata (smoking history, Eastern 
Cooperative Oncology Group performance status, disease histology, and geographical region), † Defined as the 
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Figure 2. Kaplan-Meier estimates of overall (A) and progression-free survival (B) in the 
intention-to-treat population, and of overall survival in the high (C) and low (D) EGFR 
expression subgroups of thetranslational research population 
 
Vertical lines in figure parts A and B show censored patients. Proportions censored were 79 (25%) of 315 
patients in the necitumumab pluspemetrexed and cisplatin group and 72 (23%) of 318 patients in the pemetrexed 
and cisplatin group for overall survival (A), and 84 (27%) and 79 (25%), respectively, for progression-free 
survival (B). Proportions censored were 26 (26%) of 101 patients in the necitumumab pluspemetrexed and 
cisplatin group and 27 (27%) of 99 patients in the pemetrexed and cisplatin group for patients with an EGFR H-
score >200 (C), and 29 (20%) of 144 patients and 24 (16%) of 146 patients, respectively, for patients with an 




Our findings provide no evidence to show that the addition of necitumumab to pemetrexed 
and cisplatin as first-line therapy improves overall survival in patients with stage IV non-
squamous NSCLC. The statistical power of the study was reduced by its early curtailment. 
Nevertheless, the HR for death in the final analysis and the consistent absence of benefit in 
other efficacy endpoints, including progression-free survival and response, suggest that 
addition of necitumumab to pemetrexed and cisplatin is unlikely to improve the outcome in 
this setting (panel). The reason for this absence of necitumumab benefit is not clear. Notably, 
findings from the randomised phase 3 SELECT trial
23 
showed no benefit of addition of 
cetuximab to pemetrexed in patients with NSCLC who had had progressive disease during or 
after one previous platinum-based chemotherapy regimen. 
Although termination of enrolment and the conditions for continuation somewhat complicate 
interpretation of the safety data, the overall incidence of grade 3 or worse adverse events was 
higher in the necitumumab plus pemetrexed and cisplatin group than in the pemetrexed and 
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cisplatin group. This finding is in line with those from other randomized studies
24
   
investigating   the addition of an EGFR antibody to first-line chemotherapy regimens. This 
increased incidence was most apparent for hypomagnesaemia-associated events and skin 
reactions, side-effects that are typically associated with EGFR antibodies.
25,26
 Grade 3 or 
worse fatigue-related events were likewise reported more frequently in the necitumumab plus 
pemetrexed and cisplatin group than in the pemetrexed and cisplatin group, as were grade 3 or 
worse venous thromboembolic events. Use of necitumumab was not associated with an 
increase in the incidence of hypersensitivity or infusion-related reactions, as would be 
expected in view of the human constitution of this IgG1 antibody. 
A meta-analysis
27
 showed that use of cisplatin is associated with an increased risk of venous 
thromboembolic events compared with non-cisplatin-based chemotherapy. In patients with 
advanced solid tumours, another meta-analysis
28
 showed that use of cetuximab or 
panitumumab with platinum-based chemotherapy is associated with an increased risk of 
venous thromboembolic events compared with the same chemotherapy alone. The level of 
thromboembolic events noted in the necitumumab group in our study is therefore likely to be 
due to an additive effect from the administration of platinum doublet chemotherapy in 
conjunction with an EGFR antibody. Similarly, the relative increase in the incidence of 
venous thrombosis was similar between patients given necitumumab plus gemcitabine and 
cisplatin and those given gemcitabine and cisplatin alone in a parallel phase 3 trial that 
included only patients with squamous NSCLC.
12
 We identified no clinical variable, including 
age, ECOG performance status, smoking history, or relevant medical history that predicted for 
the development of venous thromboembolic events. However, we could not formally assess 
the relevance of previous central catheter insertion or treatment with low-molecular-weight 
heparin. We would also note that there are no clear data suggesting that prophylactic use of 
anticoagulants is effective in reducing the incidence of thromboembolic events in patients 
receiving an EGFR antibody in combination with platinum-based chemotherapy. 
Other EGFR monoclonal antibodies that have been investigated in clinical trials of patients 









 of individual patient data from four randomised studies, in which chemotherapy 
plus cetuximab was compared with chemotherapy alone for the first-line treatment of patients 
with advanced NSCLC, reported that the cetuximab survival benefit might be greater for 
patients with squamous-cell carcinoma (HR 0∙77 [95% CI 0∙64-0∙93]) than for those with 
adenocarcinoma (HR 0-94 [0∙82-1∙09]). Notably, the SQUIRE trial12 showed an overall and 
progression-free survival advantage for necitumumab plus gemcitabine and cisplatin 
compared with gemcitabine and cisplatin alone in patients with squamous NSCLC. 
 
Analysis of findings from the FLEX study
20
 suggested that a tumour EGFR 
immunohistochemistry score of 200 or more was predictive of cetuximab survival benefit. In 
an exploratory analysis of immunohistochemistry-assessable patients in this study, no 
evidence showed that a score of 200 or more was predictive of survival or other efficacy 
outcomes. Similarly, a clear differential effect of necitumumab on overall or progression-free 
survival according to an H-score cutoff of 200 was not reported in the SQUIRE trial.
12
 
However, outcomes in each treatment group in the present study were better for patients with 
high levels of tumour EGFR expression than for those with low levels, consistent with the 
prognostic value of the H-score threshold for patients in this study. In view of the overall 
absence of compelling evidence that tumour EGFR expression is a strong favourable 
prognostic indicator in patients with NSCLC,
36,38
 one possible explanation for these findings 
might be that high tumour EGFR expression is of predictive value in patients receiving 
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pemetrexed and cisplatin chemotherapy. However, overall, these data do not provide any 
additional evidence to support the predictive value of EGFR H-score in relation to EGFR-
targeted treatments. Exploratory analyses of the predictive and or prognostic value of other 
biomarkers (EGFR copy number, EGFR and KRAS mutation status, and ALK status) are 
ongoing and will be reported elsewhere. 
 
Table 3. Adverse events of interest 
 Necitumumab plus pemetrexed 
and cisplatin (n=304) 
Pemetrexed and cisplatin (n=312) 
 Any grade Grade 3 Grade 4 Grade 5 Any grade Grade 3 Grade 4 Grade 5 
Neutropenia 97 40 15 0 101 51 6 0 
 (32%) (13%) (5%)  (32%) (16%) (2%)  
 Anaemia 79 22 1 0 98 23 1 0 
 (26%) (7%) (<1%)  (31%) (7%) (<1%)  
Fatigue 169 33 1 0 159 18 1 0 




81 14 9 0 40 4 3 0 
 (27%) (5%) (3%)  (13%) (1%) (1%)  
Skin reactions 237 48 1 0 59 2 0 0 
 (78%) (16%) (<1%)  (19%) (<1%)   
Rash 230 44 1 0 49 1 0 0 
 (76%) (15%) (<1%)  (16%) (<1%)   
Hypersensitivity 
or infusion- 
6 0 0 0 4 0 0 0 
related reaction (2%)    (1%)    





 Interstitial lung 
disease 








13 4 1 3 18 6 0 5 




40 18 2 3 26 6 1 4 
events* (13%) (6%) (<1%) (1%)§ (8%) (2%) (<1%) (1%) ¶ 
Unexplained 
death* 
   11 
(4%) 
   5(2%) 
Data are n (%). Table shows data for adverse events according to composite categories of preferred terms 
grouped by medical concept. Adverse events of grade 1-2 in ≥10% of patients in either treatment group, or at 
grades 3-5 in one or more patients in either treatment group, are presented in the appendix. *Identified on the 
basis of medical review of all adverse events with an outcome of death; mainly representative of cases with no 
definitive diagnosis or with limited information aboutthe cause of death. †One cerebral ischaemia, one peripheral 
ischaemia, one myocardial infarction. ‡Three cerebrovascular accidents, one embolism, one myocardial 
infarction. §Three pulmonary embolisms. ¶Four pulmonary embolisms. 
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Panel: Research in context 
Systematic review 
We searched PubMed,with notime restriction; abstracts from the USA and international 
meetings; and trial websites including ClinicalTrials.gov, for English-language preclinical 
reports and clinical trials assessing chemotherapy in patients with lung cancer, EGFR 
therapies in these patients, and the combination of these methods. Studies about this topic 
were scarce atthetime of ourtrial design. Search terms included "lung cancer", "EGFR", and 
"targeted therapy". Supportive clinical data included a phase 1 pharmacological study
22
 of 
necitumumab in patients with advanced solid tumours, which showed that necitumumab was 
well tolerated, associated with preliminary evidence of antitumour activity, and achieved 
biologically relevant concentrations throughoutthe dosing period. The conclusion from this 
systematic review was that combining chemotherapy and anti-EGFR therapies might improve 
efficacy in patients with advanced lung cancer.The decision to study treatment-naive patients 
was based on the above literature review, and identified asan area of unmet need, because 
approved treatments in the first-line setting are associated with only modest survival and 
quality-of-life improvements at best. After discussion from clinicians, researchers, and 
regulatory bodies, we decided that efficacy endpoints such as overall survival and 
progression-free survival were the best outcomes for a clinical trial of this population. 
Interpretation 
Ourfindings show that addition of necitumumab to pemetrexed ancisplatin did not improve 
efficacy or safety outcomes in this unselected population of patients receiving first-line 
therapy for advanced non-squamous non-small-cell lung cancer. Moreover, no evidence 
suggested a predictive association between an EGFR H-score of 200 or more and survival for 
necitumumab plus pemetrexed and cisplatin in this setting. Additional analyses of exploratory 
biomarkers are ongoing. 
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